Mr. C----Diffuse Large B-cell Lymphoma (DLBCL)

This patient, Mr. C, hails from India and is 55 years old. In early 2019, he presented with persistent systemic lymphadenopathy and sought medical attention at our facility. Extensive evaluations were conducted, leading to the diagnosis of Diffuse Large B-Cell Lymphoma (DLBCL). Given the aggressive nature of DLBCL, immediate treatment initiation was crucial to address the condition effectively.

Before undergoing CAR-T therapy, Mr. C underwent a series of outpatient clinic experiences involving various chemotherapy regimens. Initially, he received RCHOP as first-line therapy, followed by subsequent treatments including REPOCH, R2-ICE, GEMOX-BTKi, Pola-BR, GB261, TQB2916, GA 101-Cedarbenamine-Doxil, and finally, Inotuzumab. While these treatments were administered over a span of time and showed some efficacy, they failed to achieve disease control, underscoring the aggressive nature of Mr. C's DLBCL.

Given the lack of satisfactory response to conventional therapies and the rapid progression of his condition, Mr. C was identified as a candidate for CAR-T cell therapy. Following meticulous preparatory procedures, Mr. C underwent CAR-T cell therapy in early 2020. This innovative treatment approach involves modifying a patient's own T cells to target and attack cancer cells more effectively.

Twenty-eight days after the reinfusion of CAR-T cells, significant disease remission was observed, marking the success of the treatment. This outcome brought renewed hope and optimism to Mr. C and his healthcare team. The remarkable response to CAR-T therapy highlights the potential of immunotherapy in treating aggressive hematologic malignancies like DLBCL.

Moving forward, Mr. C will undergo continued surveillance and follow-up appointments to monitor his condition closely. Long-term disease control and stability are essential goals of his ongoing care plan. The successful outcome of CAR-T therapy underscores the importance of personalized and innovative approaches in the management of complex cancers, offering promising prospects for patients like Mr. C.

Before & 28 days after